DARE Historical PE Ratio Notes

— Dare Bioscience (ticker symbol: DARE) is a clinical-stage biopharmaceutical company focused on developing innovative products for women's reproductive health. Their pipeline targets areas like contraception, vaginal health, sexual health, and fertility, addressing unmet medical needs with novel therapies and devices. Since Dare's revenue-generating products are still in development or early commercialization, the company has historically reported low or negative earnings. This has a direct impact on its historical price-to-earnings (PE) ratio, as companies with little to no earnings—or those operating at a loss—either have extremely high PE ratios or none at all (shown as ȁcN/Aȁd in many tables). As you review DARE's historical price, earnings, and PE ratio charts, you'll likely notice significant volatility or missing PE values during periods of negative net income. This is common for early-stage biotech firms, where investor sentiment & expectation for future success, rather than current profitability, drive stock prices. Understanding Dare's stage of development and its long runway for commercialization is crucial for interpreting the historical PE ratio & putting it into context relative to the overall biotech sector.

On this page we presented the Dare Bioscience Historical PE Ratio information for Dare Bioscience' stock. The average DARE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DARE historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DARE historical PE result, against the recent PE: when this page was posted on 5/7/2026, the most recent closing price for DARE had been 2.91, and the most recent quarterly earnings result, annualized, was 6.08. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent DARE PE on 5/7/2026 based on annualized quarterly EPS was 0.5. Based on DARE's history, that recent PE is low relative to the historical average, with the recent PE 16.7% lower than the historical average PE across our data set for Dare Bioscience.

For self directed investors doing their due diligence on DARE or any other given stock, valuation analysis for DARE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Dare Bioscience PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DARE. Thanks for visiting, and the next time you need to research DARE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.